Sotac Pharmaceuticals Ltd (SOTAC) Share Price & Fundamentals

What we do

Sotac Pharmaceuticals Ltd is a pharmaceutical manufacturer specialized in tablets, capsules, syrups, and external formulations across multiple therapeutic segments.

Founded in

2,015

Market share

A recognized pharma manufacturer with a broad product portfolio serving multiple marketers and contract manufacturing clients in India.

Problem solved

Provides reliable pharmaceutical manufacturing solutions for diverse formulations meeting rising demand in healthcare and nutrition sectors.

Top clients or who we serve

Serves pharmaceutical marketers and companies through loan license and contract manufacturing, primarily in B2B segments.

Key management

Sharadkumar Dashrathbhai Patel (Chairman & Managing Director), Dineshkumar Babulal Gelot (Whole-time Director).

Our journey and innovations

Founded in 2015, transitioned from partnership to public limited company. Expanded manufacturing capacity and acquired key subsidiaries to broaden capabilities.

Where we operate

Primarily operating in India with manufacturing and R&D facilities based in Gujarat.

Top products or what we offer

Wide range of products including Anti-Diabetic, Anti-Psychotic, Vitamins, Cardiac, Anti-Bacterial, Derma products, and complex generics.

Top brands

-

Raw materials needed

Pharmaceutical raw materials including active pharmaceutical ingredients and excipients.

Raw materials supplier

Not specified.

Recurring vs cyclical contribution

Revenue primarily from recurring contract manufacturing and license-based production agreements.

Our industry position

Growing pharma manufacturer with enhanced capacities and strategic subsidiaries, focusing on complex generics and regulated markets.

Financial highlights

FY 2024-25 consolidated revenue approx. Rs 97 crore; net profit Rs 8 crore; steady profitability with growth in consolidated net profit.

Geographical revenue split

Revenue largely from Indian markets.

Order book

-

Whats driving growth

Expansion of manufacturing capacity, strategic acquisitions, and contract agreements fuel growth.

Our future plans

Developing new manufacturing units, enhancing R&D, and targeting regulated and emerging pharma markets.

Our green promise

Engaged in CSR activities promoting environmental sustainability like tree plantation drives.

Our people and values

Governed by experienced leadership, fostering transparency, ethics, and compliance.

Key challenges ahead

Regulatory compliance delays and industry competition.

Interesting facts

Completed IPO in 2023 raising Rs 33 crore; owns subsidiaries focusing on healthcare and research.

Risks and strategy

Mitigates risk via diversified product profile, internal controls, and adherence to regulatory standards.